184 related articles for article (PubMed ID: 15922476)
1. Neutralization of tumor necrosis factor abrogates hepatic failure induced by alpha-galactosylceramide without attenuating its antitumor effect in aged mice.
Inui T; Nakashima H; Habu Y; Nakagawa R; Fukasawa M; Kinoshita M; Shinomiya N; Seki S
J Hepatol; 2005 Oct; 43(4):670-8. PubMed ID: 15922476
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the synthetic ligand-mediated function of liver NK1.1Ag+ T cells in mice by interleukin-12 pretreatment.
Habu Y; Uchida T; Inui T; Nakashima H; Fukasawa M; Seki S
Immunology; 2004 Sep; 113(1):35-43. PubMed ID: 15312134
[TBL] [Abstract][Full Text] [Related]
3. A critical role for IFN regulatory factor 1 in NKT cell-mediated liver injury induced by alpha-galactosylceramide.
Cao Z; Dhupar R; Cai C; Li P; Billiar TR; Geller DA
J Immunol; 2010 Aug; 185(4):2536-43. PubMed ID: 20624945
[TBL] [Abstract][Full Text] [Related]
4. Activation of mouse natural killer T cells accelerates liver regeneration after partial hepatectomy.
Nakashima H; Inui T; Habu Y; Kinoshita M; Nagao S; Kawaguchi A; Miura S; Shinomiya N; Yagita H; Seki S
Gastroenterology; 2006 Nov; 131(5):1573-83. PubMed ID: 17064698
[TBL] [Abstract][Full Text] [Related]
5. Age-associated augmentation of the synthetic ligand- mediated function of mouse NK1.1 ag(+) T cells: their cytokine production and hepatotoxicity in vivo and in vitro.
Inui T; Nakagawa R; Ohkura S; Habu Y; Koike Y; Motoki K; Kuranaga N; Fukasawa M; Shinomiya N; Seki S
J Immunol; 2002 Dec; 169(11):6127-32. PubMed ID: 12444115
[TBL] [Abstract][Full Text] [Related]
6. Mice deficient in Vbeta8+NKT cells are resistant to experimental hepatitis but are partially susceptible to generalised Shwartzman reaction.
Habu Y; Shinomiya N; Kinoshita M; Matsumoto A; Kawabata T; Seki S
Clin Exp Med; 2007 Mar; 7(1):30-8. PubMed ID: 17380303
[TBL] [Abstract][Full Text] [Related]
7. Functional alterations of liver innate immunity of mice with aging in response to CpG-oligodeoxynucleotide.
Kawabata T; Kinoshita M; Inatsu A; Habu Y; Nakashima H; Shinomiya N; Seki S
Hepatology; 2008 Nov; 48(5):1586-97. PubMed ID: 18925636
[TBL] [Abstract][Full Text] [Related]
8. Role of Valpha 14 NKT cells in the development of impaired liver regeneration in vivo.
Ito H; Ando K; Nakayama T; Taniguchi M; Ezaki T; Saito K; Takemura M; Sekikawa K; Imawari M; Seishima M; Moriwaki H
Hepatology; 2003 Nov; 38(5):1116-24. PubMed ID: 14578850
[TBL] [Abstract][Full Text] [Related]
9. Activation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors.
Biburger M; Tiegs G
J Leukoc Biol; 2008 Jul; 84(1):264-79. PubMed ID: 18407967
[TBL] [Abstract][Full Text] [Related]
10. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.
Nakagawa R; Nagafune I; Tazunoki Y; Ehara H; Tomura H; Iijima R; Motoki K; Kamishohara M; Seki S
J Immunol; 2001 Jun; 166(11):6578-84. PubMed ID: 11359810
[TBL] [Abstract][Full Text] [Related]
12. Enhanced gamma interferon production through activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis.
Kawakami K; Kinjo Y; Yara S; Uezu K; Koguchi Y; Tohyama M; Azuma M; Takeda K; Akira S; Saito A
Infect Immun; 2001 Nov; 69(11):6643-50. PubMed ID: 11598033
[TBL] [Abstract][Full Text] [Related]
13. Prevention of injury-induced suppression of T-cell immunity by the CD1d/NKT cell-specific ligand alpha-galactosylceramide.
Tulley JM; Palmer JL; Gamelli RL; Faunce DE
Shock; 2008 Feb; 29(2):269-77. PubMed ID: 17693934
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of lipopolysaccharide-induced nitric oxide production by alpha-galactosylceramide in mouse peritoneal cells.
Ito H; Koide N; Morikawa A; Hassan F; Islam S; Tumurkhuu G; Mori I; Yoshida T; Kakumu S; Moriwaki H; Yokochi T
J Endotoxin Res; 2005; 11(4):213-9. PubMed ID: 16176657
[TBL] [Abstract][Full Text] [Related]
15. Effects of cyclosporin A on the activation of natural killer T cells induced by alpha-galactosylceramide.
Kajiwara T; Tomita Y; Okano S; Iwai T; Yasunami Y; Yoshikai Y; Nomoto K; Yasui H; Tominaga R
Transplantation; 2007 Jan; 83(2):184-92. PubMed ID: 17264815
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of whole body hyperthermia with alpha-galactosylceramide in a subcutaneous tumor model of colon cancer.
Hattori T; Kokura S; Okuda T; Okayama T; Takagi T; Handa O; Naito Y; Yoshida N; Yoshikawa T
Int J Hyperthermia; 2007 Nov; 23(7):591-8. PubMed ID: 18038289
[TBL] [Abstract][Full Text] [Related]
17. Decreased expressions of CD1d molecule on liver dendritic cells in subcutaneous tumor bearing mice.
Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Yamamoto M; Fujita Y; Miyagi T; Ohkawa K; Hayashi N
J Hepatol; 2008 Nov; 49(5):779-86. PubMed ID: 18760855
[TBL] [Abstract][Full Text] [Related]
18. Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells.
Biburger M; Tiegs G
J Immunol; 2005 Aug; 175(3):1540-50. PubMed ID: 16034092
[TBL] [Abstract][Full Text] [Related]
19. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
[TBL] [Abstract][Full Text] [Related]
20. Suppression of eosinophilic airway inflammation by treatment with alpha-galactosylceramide.
Morishima Y; Ishii Y; Kimura T; Shibuya A; Shibuya K; Hegab AE; Iizuka T; Kiwamoto T; Matsuno Y; Sakamoto T; Nomura A; Taniguchi M; Sekizawa K
Eur J Immunol; 2005 Oct; 35(10):2803-14. PubMed ID: 16163669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
